PT  - JOURNAL ARTICLE
AU  - Holden, Tobias M
AU  - Richardson, Reese A.K.
AU  - Arevalo, Philip
AU  - Duffus, Wayne A.
AU  - Runge, Manuela
AU  - Whitney, Elena
AU  - Wise, Leslie
AU  - Ezike, Ngozi O.
AU  - Patrick, Sarah
AU  - Cobey, Sarah
AU  - Gerardin, Jaline
TI  - Geographic and demographic heterogeneity of SARS-CoV-2 diagnostic testing in Illinois, USA, March to December 2020
AID  - 10.1101/2021.04.14.21255476
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.04.14.21255476
4099  - http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255476.short
4100  - http://medrxiv.org/content/early/2021/04/20/2021.04.14.21255476.full
AB  - Background Availability of SARS-CoV-2 testing in the United States (U.S.) has fluctuated through the course of the COVID-19 pandemic, including in the U.S. state of Illinois. Despite substantial ramp-up in test volume, access to SARS-CoV-2 testing remains limited, heterogeneous, and insufficient to control spread.Methods We compared SARS-CoV-2 testing rates across geographic regions, over time, and by demographic characteristics (i.e., age and racial/ethnic groups) in Illinois during March through December 2020. We compared age-matched case fatality ratios and infection fatality ratios through time to estimate the fraction of SARS-CoV-2 infections that have been detected through diagnostic testing.Results By the end of 2020, initial geographic differences in testing rates had closed substantially. Case fatality ratios were higher in non-Hispanic Black and Hispanic/Latino populations in Illinois relative to non-Hispanic White populations, suggesting that tests were insufficient to accurately capture the true burden of COVID-19 disease in the minority populations during the initial epidemic wave. While testing disparities decreased during 2020, Hispanic/Latino populations consistently remained the least tested at 1.87 tests per 1000 population per day compared with 2.58 and 2.87 for non-Hispanic Black and non-Hispanic White populations, respectively, at the end of 2020. Despite a large expansion in testing since the beginning of the first wave of the epidemic, we estimated that over half (50-80%) of all SARS-CoV-2 infections were not detected by diagnostic testing and continued to evade surveillance.Conclusions Systematic methods for identifying relatively under-tested geographic regions and demographic groups may enable policymakers to regularly monitor and evaluate the shifting landscape of diagnostic testing, allowing officials to prioritize allocation of testing resources to reduce disparities in COVID-19 burden and eventually reduce SARS-CoV-2 transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementTH was supported by a grant from NIGMS (T32 GM008152). RR was supported by a grant from NIGMS (T32 GM008449). MR was supported by a COVID-19 rapid response grant via NUCATS (UL1TR001422). The funders had no role in the design of the study and collection, analysis, and interpretation of data or in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was carried out as part of a Medical Study (Modeling COVID-19 Epidemiologic Trend and Health Care Impact in Illinois) declared by the Illinois Department of Public Health (IDPH) on March 23, 2020. All data collection was performed by IDPH as part of routine surveillance for COVID-19 and was deidentified prior to analysis. CDC has determined that this study does not constitute human subjects research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe I-NEDSS and testing by age and race/ethnicity datasets analyzed in this study were used under license for the current study, and so are not publicly available. Restrictions apply to the availability of these data, which contain identifiable private health information. Interested parties should contact IDPH to inquire about access. Public data on cases and testing are available from IDPH (https://www.dph.illinois.gov/covid19/covid19-statistics) and from other public aggregators (https://coronavirus.jhu.edu/region/us/illinois). https://www.dph.illinois.gov/covid19/covid19-statistics https://coronavirus.jhu.edu/region/us/illinois ACSAmerican Community SurveyCFRcase fatality ratioHFRhospital fatality ratioIDPHIllinois Department of Public HealthIFRinfection fatality ratioI-NEDSSIllinois’s National Electronic Disease Surveillance SystemNCHSNational Center for Health StatisticsUIUCUniversity of Illinois at Urbana-Champaign